KRYS: Krystal Biotech, Inc. Company Short-Term Debt

Symbol and logo of brand Krystal Biotech, Inc. (KRYS)

The current volume of short-term loans correlates with the commercialization of Vyjuvek and the management of cash flows for Krystal Biotech, Inc. (KRYS). The value of 0.00 reflects this status, confirming the company's position as an innovator in the treatment of rare skin pathologies. The business's success relies on the authority of Krish Krishnan's team, whose R&D competencies ensured the market launch of the first topical gene therapy.

KRYS (Krystal Biotech Inc) Company Short-Term Debts history from 07/04/2022 to 10/31/2026

Metric breakdowns and analytics for Krystal Biotech Corp. (KRYS)

- current quotes and average value forecast:
Price Chart Krystal Biotech|KRYS - Fair Value Consensus
- market capitalization information:
Market Value Krystal Biotech, Inc.|KRYS - Real Price to Acquire Entire Company
- shareholders' equity book value data:
Book Value per Share Krystal Biotech|KRYS - Book Capitalization|Market Cap to Net Assets Ratio krystalbio.com|KRYS - Aggregate Asset Value
- debt and liquidity data:
Debt to Equity Krystal Biotech, Inc.|KRYS - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Equity Krystal Biotech, Inc.|KRYS - Company Aggregate Debts|Debts to Book Capitalization Krystal Biotech, Inc.|KRYS - Long-Term Debt Volume|Company Short-Term Debt Krystal Biotech|Quick Liquidity krystalbio.com
- net income and valuation multiples indicators:
KRYS - Net Profit
Analysis of all company metrics:Krystal Biotech (KRYS)
Mass-produced product of Krystal Biotech, Inc.

This indicator measures the aggregate volume of borrowed funds with a maturity horizon of up to one year, allowing for an assessment of current liquidity and the risk of working capital deficits. By analyzing short-term balance sheet liabilities on GURU.Markets, an investor can benchmark the debt load of Krystal Biotech, Inc. (KRYS) against industry peers to evaluate the company's ability to fund the maintenance of the ANCOR sterile plant without a critical increase in leverage.

Competitors of Krystal Biotech, Inc.

APGE - Company Short-Term Debt|Company Short-Term Loans and Borrowings ARQT (Arcutis)|Vericel Corp. (VCEL) - Company Short-Term Debt|Company Current Liabilities Oruka Pharma|SMTI (Sanara MedTech, Inc.) - Company Short-Term Debts|Company Short-Term Debts DBV Technologies SA|Company Current Liabilities SLSN (Solesence Inc)|DERM (journeymedicalcorp.com) - Company Short-Term Loans and Borrowings|Company Short-Term Debt Forte Biosciences, Inc FBRX|Short-Term Debt Volume Empro Corporation (EMPG)|SLGL - Company Short-Term Debt|AXIL - Company Short-Term Debts|MDCX: Company Short-Term Debts|VRCA - Short-Term Debt Volume|Company Short-Term Debt Hoth Therapeutics Inc.|Company Short-Term Indebtedness BFRI (Biofrontera Inc)|Company Short-Term Debt VYNE Therapeutics (VYNE)|Company Short-Term Debts sonomapharma.com (SNOA)|Company Short-Term Debt Quoin Pharmaceuticals Ltd. QNRX|Company Short-Term Loans and Borrowings AZTR|DRMA: Company Current Liabilities|Short-Term Debt Elevai Corp|Revance Therapeutics (RVNC) - Company Short-Term Debt